Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.4 million.

Halozyme Therapeutics sees FY2015 revenue of $85-95 million, versus the consensus of $93.3 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.